Key Takeaways Moderna reports Q3 2025 results on Nov. 6, with forecasts showing lower sales and wider losses.COVID-19 vaccine revenue is expected to fall sharply amid weaker demand for boosters.The CMV vaccine failure clouds Moderna's growth plans despite a strong cash position and broad pipeline.Moderna (MRNA) is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $860 million and a loss of$2.15 per share, respectiv ...